Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder.
- Published in:
- CNS Drugs, 2023, v. 37, n. 1, p. 93, doi. 10.1007/s40263-022-00980-8
- By:
- Publication type:
- Article
Works matching IS 11727047 AND DT 2023 AND VI 37 AND IP 1
Results: 7
1
2
Treatment Outcomes of Newly Diagnosed Epilepsy: A Systematic Review and Meta-analysis.
- Published in:
- CNS Drugs, 2023, v. 37, n. 1, p. 13, doi. 10.1007/s40263-022-00979-1
- By:
- Publication type:
- Article
3
Early Morning ADHD Symptoms and Functional Impairment: Impact on Patients and Caregivers, and Pharmacological Approaches to Management.
- Published in:
- CNS Drugs, 2023, v. 37, n. 1, p. 31, doi. 10.1007/s40263-022-00978-2
- By:
- Publication type:
- Article
4
Treatment of Patients with Multiple Sclerosis Transitioning Between Relapsing and Progressive Disease.
- Published in:
- CNS Drugs, 2023, v. 37, n. 1, p. 69, doi. 10.1007/s40263-022-00977-3
- By:
- Publication type:
- Article
5
A 10-Year Observational Study of the Use, Acceptability and Effectiveness of Long-Acting Paliperidone Palmitate: Implications for Clinical Decision Making.
- Published in:
- CNS Drugs, 2023, v. 37, n. 1, p. 107, doi. 10.1007/s40263-022-00976-4
- By:
- Publication type:
- Article
6
Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases.
- Published in:
- CNS Drugs, 2023, v. 37, n. 1, p. 45, doi. 10.1007/s40263-022-00975-5
- By:
- Publication type:
- Article
7
Orexin Receptor Antagonists in the Treatment of Depression: A Leading Article Summarising Pre-clinical and Clinical Studies.
- Published in:
- CNS Drugs, 2023, v. 37, n. 1, p. 1, doi. 10.1007/s40263-022-00974-6
- By:
- Publication type:
- Article